Literature DB >> 19699534

Endothelium negatively modulates the vascular relaxation induced by nitric oxide donor, due to uncoupling NO synthase.

Daniella Bonaventura1, Claure N Lunardi, Gerson J Rodrigues, Mário A Neto, Juliana A Vercesi, Renata G de Lima, Roberto S da Silva, Lusiane M Bendhack.   

Abstract

Nitrosyl ruthenium complexes have been characterized as nitric oxide (NO) donors that induce relaxation in the denuded rat aorta. There are some differences in their vascular relaxation mechanisms compared with sodium nitroprusside. This study investigates whether the endothelium could interfere with the [Ru(terpy)(bdq)NO](3+)-TERPY-induced vascular relaxation, by analyzing the maximal relaxation (Emax) and potency (pD(2)) of TERPY. Vascular reactivity experiments showed that the endothelium negatively modulates (pD(2): 6.17+/-0.07) the TERPY relaxation in intact rat aortic rings compared with the denuded rat aorta (pD(2): 6.65+/-0.07). This effect is abolished by a non-selective NO-synthase (NOS) inhibitor L-NAME (pD(2): 6.46+/-0.10), by the superoxide anion (O(2)(-)) scavenger TIRON (pD(2): 6.49+/-0.08), and by an NOS cofactor BH(4) (pD(2): 6.80+/-0.10). The selective dye for O(2)(-) (DHE) shows that TERPY enhances O(2)(-) concentration in isolated endothelial cells (intensity of fluorescence (IF):11258.00+/-317.75) compared with the basal concentration (IF: 7760.67+/-381.50), and this enhancement is blocked by L-NAME (IF: 8892.33+/-1074.41). Similar results were observed in vascular smooth muscle cells (concentration of superoxide after TERPY: 2.63+/-0.17% and after TERPY+L-NAME: -4.63+/-0.14%). Considering that TERPY could induce uncoupling NOS, thus producing O(2)(-), we have also investigated the involvement of prostanoids in the negative modulation of the endothelium. The non-selective cyclooxygenase (COX) inhibitor indomethacin and the selective tromboxane (TXA(2)) receptor antagonist SQ29548 reduce the effect of the endothelium on TERPY relaxation (pD(2) INDO: 6.80+/-0.17 and SQ29548: 6.85+/-0.15, respectively). However, a selective prostaglandin F(2alpha) receptor antagonist (AH6809) does not change the endothelium effect. Moreover, TERPY enhances the concentration of TXA(2) stable metabolite (TXB(2)), but this effect is blocked by L-NAME and TIRON. The present findings indicate that TERPY induces uncoupling of eNOS, enhancing O(2)(-) concentration. This enhancement in O(2)(-) concentration induces COX activation, producing TXA(2), which negatively modulates the rat aorta relaxation induced by the NO donor TERPY.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699534     DOI: 10.1016/j.jinorgbio.2009.07.015

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  4 in total

1.  Individual variation and intraclass correlation in arachidonic acid and eicosapentaenoic acid in chicken muscle.

Authors:  Anna Haug; Ingrid Olesen; Olav A Christophersen
Journal:  Lipids Health Dis       Date:  2010-04-15       Impact factor: 3.876

2.  Nitric oxide donor [Ru(terpy)(bdq)NO]3+ induces uncoupling and phosphorylation of endothelial nitric oxide synthase promoting oxidant production.

Authors:  Simone R Potje; Zhenlong Chen; Suellen D'Arc S Oliveira; Lusiane M Bendhack; Roberto S da Silva; Marcelo G Bonini; Cristina Antoniali; Richard D Minshall
Journal:  Free Radic Biol Med       Date:  2017-09-09       Impact factor: 7.376

3.  The new nitric oxide donor cyclohexane nitrate induces vasorelaxation, hypotension, and antihypertensive effects via NO/cGMP/PKG pathway.

Authors:  Leônidas das G Mendes-Júnior; Driele D Guimarães; Danilo D A Gadelha; Thiago F Diniz; Maria C R Brandão; Petrônio F Athayde-Filho; Virginia S Lemos; Maria do S França-Silva; Valdir A Braga
Journal:  Front Physiol       Date:  2015-08-31       Impact factor: 4.566

4.  Contribution of oxidative stress to endothelial dysfunction in hypertension.

Authors:  Bruno R Silva; Laena Pernomian; Lusiane M Bendhack
Journal:  Front Physiol       Date:  2012-12-05       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.